2025 United Kingdom Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 United Kingdom Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Antibody Drug Conjugates (ADC) contract manufacturing in the United Kingdom are Piramal Pharma Solutions, Sterling Pharma Solutions, Catalent, Inc., and Lonza Group. Piramal Pharma Solutions operates a significant ADC manufacturing facility in Grangemouth, Scotland, which underwent a £45 million expansion in 2023, increasing production capacity by 70-80%, and is equipped with five dedicated GMP suites for clinical and commercial manufacturing. Sterling Pharma Solutions, based in Deeside, Wales, also expanded its capacity recently, investing over £10 million to more than double its clinical-scale ADC bioconjugation capacity with 500-liter reactors and new cleanroom facilities.
Catalent, Inc. and Lonza Group are global leaders in biopharmaceutical manufacturing with advanced capabilities supporting early-stage development to commercial-scale production of ADCs. Both have a growing presence in the UK's ADC contract manufacturing market, contributing to the country’s anticipated USD 450.2 million market size by 2030 with a CAGR of 10.2% from 2025 to 2030. These companies benefit from innovations in bio-manufacturing technologies and strong regulatory compliance, underpinning the UK's commitment to expanding its role in ADC production and cancer therapy development.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Antibody Drug Conjugates (ADC) contract manufacturing in the United Kingdom are Piramal Pharma Solutions, Sterling Pharma Solutions, Catalent, Inc., and Lonza Group. Piramal Pharma Solutions operates a significant ADC manufacturing facility in Grangemouth, Scotland, which underwent a £45 million expansion in 2023, increasing production capacity by 70-80%, and is equipped with five dedicated GMP suites for clinical and commercial manufacturing. Sterling Pharma Solutions, based in Deeside, Wales, also expanded its capacity recently, investing over £10 million to more than double its clinical-scale ADC bioconjugation capacity with 500-liter reactors and new cleanroom facilities.
Catalent, Inc. and Lonza Group are global leaders in biopharmaceutical manufacturing with advanced capabilities supporting early-stage development to commercial-scale production of ADCs. Both have a growing presence in the UK's ADC contract manufacturing market, contributing to the country’s anticipated USD 450.2 million market size by 2030 with a CAGR of 10.2% from 2025 to 2030. These companies benefit from innovations in bio-manufacturing technologies and strong regulatory compliance, underpinning the UK's commitment to expanding its role in ADC production and cancer therapy development.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
